Search results for "Renal failure"

showing 6 items of 56 documents

Polymorphonuclear leucocyte rheology and cytosolic Ca2+ content after activation in chronic renal failure

2001

SUMMARY: We evaluated polymorphonuclear leucocyte (PMN) flow properties in patients with clinically stable chronic renal failure (CRF) and in control subjects at baseline and after activation with 4-phorbol 12-myristate 13-acetate (PMA) and N-formyl-methionyl-leucyl-phenylalanine (fMLP). Initial relative flow rate (IRFR) and clogging particles (CPs) were obtained using the St. George's Filtrometer, and PMN membrane fluidity was assessed by marking PMNs with 1-(4-(trimethylamino)phenyl)-6-phenyl-1,3,5-hexatriene (TMA-DPH). PMN cytosolic Ca2+ concentration was determined by marking PMNs with Fura 2-AM. At baseline, CRF patients showed a significant increase only in PMN cytosolic Ca2+ content.…

medicine.medical_specialtybusiness.industryhemic and immune systemsGeneral MedicineControl subjectsPolymorphonuclear leucocyteCytosolEndocrinologyNephrologyInternal medicineImmunologymedicineMembrane fluidityChronic renal failureIn patientFlow propertiesbusinessNephrology
researchProduct

Zero-contrast percutaneous coronary intervention of saphenous vein graft in a patient with chronic renal failure

2018

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectSaphenous vein graftlcsh:RPercutaneous coronary interventionlcsh:MedicineText miningImage in InterventionInternal medicinemedicineCardiologyChronic renal failureContrast (vision)Cardiology and Cardiovascular Medicinebusinessmedia_commonAdvances in Interventional Cardiology
researchProduct

Use of neural networks for dosage individualisation of erythropoietin in patients with secondary anemia to chronic renal failure.

2003

The external administration of recombinant human erythropoietin is the chosen treatment for those patients with secondary anemia due to chronic renal failure undergoing periodic hemodialysis. The goal is to carry out an individualised prediction of the erythropoietin dosage to be administered. It is justified because of the high cost of this medication, its secondary effects and the phenomenon of potential resistance which some individuals suffer. One hundred and ten patients were included in this study and several factors were collected in order to develop the neural models. Since the results obtained were excellent, an easy-to-use decision-aid computer application was implemented.

medicine.medical_specialtymedicine.diagnostic_testAnemiaSecondary anemiabusiness.industrymedicine.medical_treatmentHealth InformaticsAnemiamedicine.diseaseRecombinant ProteinsComputer Science ApplicationsTherapeutic drug monitoringErythropoietinmedicineQuality of LifeChronic renal failureHumansKidney Failure ChronicIn patientHemodialysisNeural Networks ComputerIntensive care medicinebusinessErythropoietinmedicine.drugComputers in biology and medicine
researchProduct

Nitric oxide metabolites in chronic renal failure in conservative and in haemodialysis treatment.

2008

nitric oxidechronic renal failure
researchProduct

Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group…

2021

Background: Preservation of kidney function in newly diagnosed (ND) multiple myeloma (MM) helps to prevent excess toxicity. Patients (pts) from two prospective trials were analyzed, provided postinduction (PInd) restaging was performed. Pts received three cycles with bortezomib (btz), cyclophosphamide, and dexamethasone (dex

renal failurekidneyendocrine systemCancer Researchmedicine.medical_specialtyCyclophosphamide030232 urology & nephrologyUrologyRenal functionlcsh:RC254-282NiereninsuffizienzArticleBortezomib03 medical and health sciences0302 clinical medicineMultiple myelomamedicineddc:610Renal insufficiencyLenalidomideDexamethasoneMultiple myelomaLenalidomideKidneybusiness.industryBortezomiblcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensinduction regimenmedicine.disease3. Good healthmedicine.anatomical_structureOncology030220 oncology & carcinogenesisPlasmozytombusinessDDC 610 / Medicine & healthKidney diseasemedicine.drugCancers
researchProduct

EtG Quantification in Hair and Different Reference Cut-Offs in Relation to Various Pathologies: A Scoping Review

2022

Ethyl glucuronide (EtG) is a non-volatile, non-oxidative, hydrophilic, and stable ethanol phase II metabolite. EtG is produced through ethanol glucuronidation by UDP-glucuronosyltransferase (UGT), a phase II enzyme. EtG can be extracted from different biological matrices, including keratin ones, such as hair or nails. The purpose of this scoping review is to describe the relationship between EtG levels in hair and some of the most common and frequent pathological conditions and verify whether different reference cut-offs in relation to various pathologies have been identified in the scientific literature. In fact, in-depth knowledge of the influence of pathologies, such as diabetes mellitus…

renal failure.Chemical Health and Safetyalcoholdiabetes mellituHealth Toxicology and Mutagenesisethyl glucuronide (EtG)forensic medicinehairethanolforensic toxicologyToxicologyliver disease
researchProduct